Health & Wellness | Toronto Caribbean Newspaper
Magic mushrooms are moving mainstream
BY W. GIFFORD- JONES MD & DIANA GIFFORD-JONES You may have preconceived ideas that magic mushrooms are the party drugs of days past. However, in Canada and other countries, regulations are starting to ease on these prohibited psychedelics. The impetus stems from clinical trials showing remarkable results in treating post-traumatic stress disorder (PTSD) and treatment-resistant […]
The post Magic mushrooms are moving mainstream first appeared on Toronto Caribbean Newspaper.
2 years 5 months ago
Your Health, #LatestPost
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
MCh Urology: Admissions, Medical Colleges, Fees, Eligibility Criteria details
MCh Urology or Master of
Chirurgiae in Urology also known as MCh in Urology is a super specialty level
course for doctors in India that they do after completion of their
postgraduate medical degree course. The duration of this super specialty
course is 3 years, and it focuses on the diagnosis and treatment of diseases
MCh Urology or Master of
Chirurgiae in Urology also known as MCh in Urology is a super specialty level
course for doctors in India that they do after completion of their
postgraduate medical degree course. The duration of this super specialty
course is 3 years, and it focuses on the diagnosis and treatment of diseases
of the urinary-tract system and the reproductive organs. Organs under the
domain of urology include the kidneys, adrenal glands, ureters, urinary
bladder, urethra, and the male reproductive organs.
The course is a
full-time course pursued at various recognized medical colleges across the
country. Some of the top medical colleges offering this course include All India Institute of Medical Sciences, New Delhi, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, Atal Bihari Vajpayee Institute of Medical Sciences and Dr RML Hospital, New Delhi, and more.
Admission to this course
is done through the NEET-SS Entrance exam conducted by the National Board of
Examinations, followed by counselling based on the scores of the exam that is
conducted by DGHS/MCC/State Authorities.
The fee for pursuing MCh
(Urology) varies from college to college and may range from Rs.7 thousand to
Rs. 28 lakhs.
After completion of
their respective course, doctors can either join the job market or can pursue
certificate courses and Fellowship programmes recognized by NMC and NBE.
Candidates can take reputed jobs as Senior residents, Consultants,
etc. with an approximate salary range of Rs 4.5 lakhs to Rs. 30 lakhs per
annum.
What is MCh in Urology?
Master of Chirurgiae in Urology,
also known as MCh (Urology) or MCh in (Urology) is a three-year super
specialty programme that candidates can pursue after completing a postgraduate
degree.
MCh Urology provides
training to evaluate, understand, and manage medical and
surgical aspects of genitourinary disorders. The curriculum includes basic and
clinical research in renovascular hypertension, adult and pediatric urinary
tract infection, treatment of urinary incontinence, neuro-urology, urinary tract
physiology, anatomy and cellular biology of the prostate gland, and
genitourinary oncology.
The postgraduate
students must gain ample knowledge and experience in the diagnosis, and
treatment of patients with acute, serious, and life-threatening diseases.
PG education intends to
create specialists who can contribute to high-quality health care and advances
in science through research and training.
The required training
done by a postgraduate specialist in the field of Urology would help the
specialist to recognize the health needs of the community. The student should
be competent to handle medical problems effectively and should be aware of the
recent advances in their speciality.
The candidate is also
expected to know the principles of research methodology and modes of the
consulting library. The candidate should regularly attend conferences,
workshops and CMEs to upgrade her/ his knowledge.
Course
Highlights
Here are some of the
course highlights of MCh in Urology
Name of Course
MCh in Urology
Level
Doctorate
Duration of Course
Three years
Course Mode
Full Time
Minimum Academic Requirement
Candidates must have a postgraduate medical
Degree in MS/DNB (General Surgery) obtained from any college/university
recognized by the Medical Council of India (Now NMC)/NBE, this feeder
qualification mentioned here is as of 2022. For any further changes to the
prerequisite requirement please refer to the NBE website.
Admission Process / Entrance Process /
Entrance Modalities
Entrance Exam (NEET-SS)
INI CET for various AIIMS, PGIMER Chandigarh,
JIPMER Puducherry, NIMHANS Bengaluru
Counselling by DGHS/MCC/State Authorities
Course Fees
Rs.7 thousand to Rs. 28 lakhs per year
Average Salary
Rs 4.5 lakhs to Rs.30 lakhs per annum
Eligibility
Criteria
The eligibility criteria
for MCh in Urology are defined as the set of rules or minimum prerequisites
that aspirants must meet to be eligible for admission, which include:
Name of Super Specialty course
Course Type
Prior Eligibility Requirement
Urology
MCh
MS/DNB (General Surgery)
Note:
· The feeder
qualification for MCh Urology is defined by the NBE and is subject to changes
by the NBE.
· The feeder
qualification mentioned here is as of 2022.
· For any changes,
please refer to the NBE website.
- The prior entry qualifications
shall be strictly by Post Graduate Medical Education Regulations, 2000,
and its amendments notified by the NMC and any clarification issued from
NMC in this regard. - The candidate must have
obtained permanent registration with any State Medical Council to be
eligible for admission. - The medical college's
recognition cut-off dates for the Postgraduate Degree courses shall be as
prescribed by the Medical Council of India (now NMC).
Admission
Process
The admission process
contains a few steps to be followed in order by the candidates for admission to
MCh in Urology. Candidates can view the complete admission process for MCh in Urology
mentioned below:
- The NEET-SS or National
Eligibility Entrance Test for Super speciality courses is a national-level
master’s level examination conducted by the NBE for admission to
DM/MCh/DrNB Courses. - Qualifying Criteria-Candidates
placed at the 50th percentile or above shall be declared as qualified in
the NEET-SS in their respective speciality. - The following Medical
institutions are not covered under centralized admissions for DM/MCh
courses through NEET-SS:
1. AIIMS, New Delhi and
other AIIMS
2. PGIMER, Chandigarh
3. JIPMER, Puducherry
4. NIMHANS, Bengaluru
- Candidates from all eligible
feeder speciality subjects shall be required to appear in the question
paper of the respective group if they are willing to opt for a
super-speciality course in any of the super-speciality courses covered in
that group. - A candidate can opt for
appearing in the question papers of as many groups for which his/her
Postgraduate speciality qualification is an eligible feeder qualification. - By appearing in the question
paper of a group and on qualifying for the examination, a candidate shall
be eligible to exercise his/her choices in the counselling only for those
super-speciality subjects covered in the said group for which his/ her
broad speciality is an eligible feeder qualification.
Fees Structure
The fee structure for
MCh in Urology varies from college to college. The fee is generally less for
Government Institutes and more for private institutes. The average fee
structure for MCh in Urology is from Rs.7 thousand to Rs. 28 lakhs per year.
Colleges
offering MCh in Urology
Various medical colleges
across India offer courses for pursuing MCh in (Urology).
As per National Medical
Commission (NMC) website, the following medical colleges are offering MCh in (Urology)
courses for the academic year 2022-23.
Sl.No.
Course Name
State
Name and Address of
Medical College / Medical Institution
Management of College
Annual Intake (Seats)
1
M.Ch - Urology/Genito-Urinary Surgery
Andhra Pradesh
Andhra Medical College, Visakhapatnam
Govt.
3
2
M.Ch - Urology/Genito-Urinary Surgery
Andhra Pradesh
Sri Venkateswara Institute of Medical Sciences
(SVIMS), Tirupati
Govt.
4
3
M.Ch - Urology/Genito-Urinary Surgery
Andhra Pradesh
Dr P.S.I. Medical College, Chinoutpalli
Trust
2
4
M.Ch - Urology/Genito-Urinary Surgery
Andhra Pradesh
Guntur Medical College, Guntur
Govt.
2
5
M.Ch - Urology/Genito-Urinary Surgery
Andhra Pradesh
Narayana Medical College, Nellore
Trust
4
6
M.Ch - Urology/Genito-Urinary Surgery
Assam
Gauhati Medical College, Guwahati
Govt.
4
7
M.Ch - Urology/Genito-Urinary Surgery
Bihar
Indira Gandhi Institute of Medical
Sciences, Sheikhpura, Patna
Govt.
4
8
M.Ch - Urology/Genito-Urinary Surgery
Chandigarh
Postgraduate Institute of Medical Education &
Research, Chandigarh
Govt.
10
9
M.Ch - Urology/Genito-Urinary Surgery
Chattisgarh
All India Institute of Medical Sciences, Raipur
Govt.
2
10
M.Ch - Urology/Genito-Urinary Surgery
Delhi
All India Institute of Medical Sciences, New
Delhi
Govt.
11
11
M.Ch - Urology/Genito-Urinary Surgery
Delhi
Atal Bihari Vajpayee Institute of Medical
Sciences and Dr RML Hospital, New Delhi
Govt.
4
12
M.Ch - Urology/Genito-Urinary Surgery
Delhi
Vardhman Mahavir Medical College & Safdarjung
Hospital, Delhi
Govt.
5
13
M.Ch - Urology/Genito-Urinary Surgery
Gujarat
B J Medical College, Ahmedabad
Govt.
4
14
M.Ch - Urology/Genito-Urinary Surgery
Haryana
Maharishi Markandeshwar Institute Of Medical
Sciences & Research, Mullana, Ambala
Trust
2
15
M.Ch - Urology/Genito-Urinary Surgery
Jammu & Kashmir
Sher-I-Kashmir Instt. Of Medical Sciences,
Srinagar
Govt.
4
16
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Bangalore Medical College and Research Institute,
Bangalore
Govt.
2
17
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
S S Institute of Medical Sciences& Research
Centre, Davangere
Trust
2
18
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Vijaynagar Institute of Medical Sciences, Bellary
Govt.
4
19
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Jawaharlal Nehru Medical College, Belgaum
Trust
5
20
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Kasturba Medical College, Manipal
Trust
6
21
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Rajarajeswari Medical College & Hospital,
Bangalore
Trust
4
22
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Yenepoya Medical College, Mangalore
Trust
3
23
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Father Mullers Medical College, Mangalore
Trust
2
24
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
K S Hegde Medical Academy, Mangalore
Trust
3
25
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
A J Institute of Medical Sciences & Research
Centre, Mangalore
Trust
4
26
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Vydehi Institute Of Medical Sciences &
Research Centre, Bangalore
Trust
1
27
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
St. Johns Medical College, Bangalore
Trust
1
28
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Shri B M Patil Medical College, Hospital &
Research Centre, Vijayapura(Bijapur
Trust
3
29
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
Institute of Nephro-Urology, Bangalore
Govt.
6
30
M.Ch - Urology/Genito-Urinary Surgery
Karnataka
M S Ramaiah Medical College, Bangalore
Trust
6
31
M.Ch - Urology/Genito-Urinary Surgery
Kerala
Medical College, Thiruvananthapuram
Govt.
6
32
M.Ch - Urology/Genito-Urinary Surgery
Kerala
Government Medical College, Kottayam
Govt.
3
33
M.Ch - Urology/Genito-Urinary Surgery
Kerala
Government Medical College, Kozhikode, Calicut
Govt.
4
34
M.Ch - Urology/Genito-Urinary Surgery
Kerala
T D Medical College, Alleppey (Allappuzha)
Govt.
2
35
M.Ch - Urology/Genito-Urinary Surgery
Kerala
Amrita School of Medicine, Elamkara, Kochi
Trust
3
36
M.Ch - Urology/Genito-Urinary Surgery
Madhya Pradesh
All India Institute of Medical Sciences, Bhopal
Govt.
2
37
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Bombay Hospital Institute of Medical Sciences,
Mumbai
Govt.
2
38
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Mahatma Gandhi Missions Medical College,
Aurangabad
Trust
1
39
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Lokmanya Tilak Municipal Medical College, Sion,
Mumbai
Govt.
4
40
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Topiwala National Medical College, Mumbai
Govt.
3
41
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Seth GS Medical College, and KEM Hospital, Mumbai
Govt.
4
42
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Mahatma Gandhi Missions Medical College, Navi
Mumbai
Trust
3
43
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Bharati Vidyapeeth University Medical College,
Pune
Trust
3
44
M.Ch - Urology/Genito-Urinary Surgery
Maharashtra
Dr D Y Patil Medical College, Hospital and
Research Centre, Pimpri, Pune
Trust
4
45
M.Ch - Urology/Genito-Urinary Surgery
Manipur
Regional Institute of Medical Sciences, Imphal
Govt.
2
46
M.Ch - Urology/Genito-Urinary Surgery
Orissa
SCB Medical College, Cuttack
Govt.
5
47
M.Ch - Urology/Genito-Urinary Surgery
Pondicherry
Jawaharlal Institute of Postgraduate Medical
Education & Research, Puducherry
Govt.
3
48
M.Ch - Urology/Genito-Urinary Surgery
Pondicherry
Mahatma Gandhi Medical College & Research
Institute, Pondicherry
Trust
2
49
M.Ch - Urology/Genito-Urinary Surgery
Punjab
Dayanand Medical College & Hospital, Ludhiana
Trust
2
50
M.Ch - Urology/Genito-Urinary Surgery
Rajasthan
Sardar Patel Medical College, Bikaner
Govt.
4
51
M.Ch - Urology/Genito-Urinary Surgery
Rajasthan
SMS Medical College, Jaipur
Govt.
10
52
M.Ch - Urology/Genito-Urinary Surgery
Rajasthan
Mahatma Gandhi Medical College and Hospital,
Sitapur, Jaipur
Trust
6
53
M.Ch - Urology/Genito-Urinary Surgery
Rajasthan
National Institute of Medical Science &
Research, Jaipur
Trust
3
54
M.Ch - Urology/Genito-Urinary Surgery
Rajasthan
Dr SN Medical College, Jodhpur
Govt.
4
55
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
SRM Medical College Hospital & Research
Centre, Chengalpattu
Trust
3
56
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Sri Ramachandra Medical College & Research
Institute, Chennai
Trust
6
57
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Madras Medical College, Chennai
Govt.
8
58
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Kilpauk Medical College, Chennai
Govt.
6
59
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Christian Medical College, Vellore
Trust
5
60
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Stanley Medical College, Chennai
Govt.
5
61
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Chettinad Hospital & Research Institute,
Kanchipuram
Trust
3
62
M.Ch - Urology/Genito-Urinary Surgery
Tamil Nadu
Meenakshi Medical College and Research Institute,
Enathur
Trust
2
63
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Osmania Medical College, Hyderabad
Govt.
4
64
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Gandhi Medical College, Secunderabad
Govt.
2
65
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Nizams Institute of Medical Sciences, Hyderabad
Govt.
4
66
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Mamata Medical College, Khammam
Trust
2
67
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Kamineni Institute of Medical Sciences, Narketpally
Trust
1
68
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Chalmeda Anand Rao Institute Of Medical
Sciences, Karimnagar
Trust
1
69
M.Ch - Urology/Genito-Urinary Surgery
Telangana
Deccan College of Medical Sciences, Hyderabad
Trust
1
70
M.Ch - Urology/Genito-Urinary Surgery
Uttarakhand
All India Institute of Medical Sciences,
Rishikesh
Govt.
22
71
M.Ch - Urology/Genito-Urinary Surgery
Uttar Pradesh
Institute of Medical Sciences, BHU, Varansi
Govt.
4
72
M.Ch - Urology/Genito-Urinary Surgery
Uttar Pradesh
Sanjay Gandhi Postgraduate Institute of Medical
Sciences, Lucknow
Govt.
4
73
M.Ch - Urology/Genito-Urinary Surgery
Uttar Pradesh
King George Medical University, Lucknow
Govt.
6
74
M.Ch - Urology/Genito-Urinary Surgery
West Bengal
Institute of Postgraduate Medical Education &
Research, Kolkata
Govt.
10
75
M.Ch - Urology/Genito-Urinary Surgery
West Bengal
Nilratan Sircar Medical College, Kolkata
Govt.
2
76
M.Ch - Urology/Genito-Urinary Surgery
West Bengal
RG Kar Medical College, Kolkata
Govt.
3
77
M.Ch - Urology/Genito-Urinary Surgery
West Bengal
Calcutta National Medical College, Kolkata
Govt.
2
Syllabus
MCh in Urology is a
three years specialization course that provides training in the stream of Urology.
As
of 27/02/2022 the Competency-Based Curriculum for MCh in Urology course is not
available on the National Medical Commission's official Website. However, the
course content of AIIMS represented here can be used for reference and an idea of
what a typical Syllabus of an MCh in Urology course will contain:
SYLLABUS
It will cover a wide
spectrum of diseases of the urogenital system & retroperitoneum. Apart from
the clinical aspect of these subjects, the candidate has to acquire in-depth
knowledge of the related basic subjects like applied; anatomy; embryology,
physiology; biochemistry, pharmacology; pathology, microbiology epidemiology,
immunology etc.
1. Anatomy and
Embryology of GU tracts, adrenal & retroperitoneum.
2. Applied physiology
and biochemistry about Urology, Nephrology, renal transplantation and renovascular
hypertension.
3. Investigative urology
& Genito-urinary radiology and imaging including nuclear medicine.
4. Male Infertility,
Andrology and Urological endocrinology
5. Sexual dysfunction-
investigations and management.
6. Perioperative care,
management of urological complications and care of critically ill patients.
7. Urodynamics and
Neurology.
8. Genito-urinary
trauma.
9. Urolithiasis-Medical,
Biochemical & Surgical aspects.
10. Uro-oncology-Adult
& Paediatric
11. Reconstructive
Urology.
12. Paediatric
Urology-congenital malformations and acquired diseases.
13. Urinary tract
infections and sexually transmitted diseases.
14. Obstructive
Uropathy.
15. Renal transplantation
(including transplant immunology medical & surgical aspects).
16. Renovascular
Hypertension.
17. Gynaecological
urology.
18. Newer developments
in urology.
19. Operative
Urology-open & endoscopic
20. Endourology
21. Behavioural and
social aspects of urology.
22. Neonatal problems in
Urology.
23. Electrocoagulation,
lasers, fibre optics, instruments,
catheters, endoscopes
etc.
24. Retroperitoneal
Diseases & Management.
25. Medical aspects of kidney diseases.
26. Laparoscopic
Urologic Surgery.
Apart from the above-mentioned subjects, each candidate should have basic knowledge of the
following:
1. Biostatistics &
Epidemiology.
2. Computer Sciences.
3. Experimental &
Research methodology and Evidence-Based Medicine.
4. Scientific
presentation.
5. Cardio-pulmonary
resuscitation.
6. Ethics in medicine.
Career Options
After completing an MCh
in Urology, candidates will get employment opportunities in Government as well
as in the Private sector.
In the Government
sector, candidates have various options to choose from which include Registrar,
Senior Resident, Demonstrator, Tutor, etc.
While in the Private
sector, the options include Resident Doctor, Consultant (Urology), Visiting Consultant (Urology),
Junior Consultant (Urology), Senior Consultant (Urology), Assistant Professor (Urology), Associate Professor
(Urology).
Courses After
MCh in Urology Course
MCh in Urology is a
specialization course that can be pursued after finishing a Postgraduate
medical course. After pursuing a specialization in MCh in Urology, a candidate
could also pursue certificate courses and Fellowship programmes recognized by
NMC and NBE, where MCh in Urology is a feeder qualification.
These include
fellowships in:
·
FNB
Paediatric Urology
·
FNB
Minimal Access Urology
Frequently
Asked Questions (FAQs) –MCh in Urology Course
- Question: What is the complete full form of an MCh?
Answer: The full form of
an MCh is a Master of Chirurgiae.
- Question: What is an MCh in Urology?
Answer: MCh Urology or
Master of Chirurgiae in Urology also known as MCh in Urology is a super
specialty level course for doctors in India that they do after
completion of their postgraduate medical degree course.
- Question: What is the duration of an MCh in Urology?
Answer: MCh in Urology
is a super specialty programme of three years.
- Question: What is the eligibility of an MCh in Urology?
Answer: Candidates must
have a postgraduate medical Degree in MS/DNB (General Surgery) obtained from any college/university recognized by the
Medical Council of India (now NMC)/NBE.
- Question: What is the scope of an MCh
in Urology?
Answer: MCh in Urology
offers candidates various employment opportunities and career prospects
- Question: What is the average salary
for an MCh in Urology candidate?
Answer: The MCh in Urology
candidate’s average salary is between Rs. 4.5 lakhs to Rs. 30 lakhs per annum
depending on the experience.
- Question: Can you teach after completing an MCh Course?
Answer: Yes, the
candidate can teach in a medical college/hospital after completing an MCh
course.
2 years 5 months ago
News,Health news,NMC News,Medical Education,Medical Colleges News,Medical Courses News,Medical Universities News,Medical Admission News,Latest Medical Education News,Medical Courses
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
AbbVie gets positive EMA committee opinion for Upadacitinib to treat adults with moderate to severe Crohn's disease
North Chicago: AbbVie has announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of upadacitinib (RINVOQ, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intol
erant to either conventional therapy or a biologic agent.
"The recent CHMP recommendation to approve upadacitinib for use in Crohn's disease is a momentous step, bringing us closer to offering a first-of-its-kind, once-daily oral treatment that can make a difference for people living with this disease," said Roopal Thakkar, M.D., senior vice president, development, regulatory affairs and chief medical officer, AbbVie. "We remain steadfast in our commitment to researching and developing treatment options as part of a diverse portfolio of therapies for those living with inflammatory bowel diseases."
AbbVie's application for the approval of upadacitinib in Crohn's disease is supported by data from two induction studies, U-EXCEED and U-EXCEL, and one maintenance study, U-ENDURE. Patients receiving upadacitinib were treated with 45 mg once daily for the induction studies, and were randomized to receive either 15 mg or 30 mg once-daily doses for the maintenance study. Across all three Phase 3 studies, a significantly greater proportion of patients treated with upadacitinib achieved the co-primary endpoints of clinical remission per SF/AP (defined as average daily stool frequency [SF] ≤2.8 and abdominal pain [AP] score ≤1.0 and neither greater than baseline) and endoscopic response (defined as decrease in simple endoscopic score for Crohn's disease [SES-CD] >50% from baseline of the induction) compared to placebo.
In all three studies, a statistically significant greater proportion of patients treated with upadacitinib achieved the key secondary endpoint of endoscopic remission (defined as SES-CD ≤4 and at least a 2-point reduction vs. baseline and no subscore >1). Additionally, more upadacitinib-treated patients achieved SES-CD ulcerated surface subscore of 0 at weeks 12 and 52 (nominal p-value<0.001) in patients with SES-CD ulcerated surface subscore ≥1 at baseline. Absence or disappearance of ulceration coupled with improvements seen by endoscopy are associated with mucosal healing.
The safety profile of upadacitinib in Crohn's disease was generally consistent with the known safety profile of upadacitinib.
"The impact of Crohn's disease extends beyond the gut to include systemic symptoms such as fatigue, bowel symptoms and social and emotional functioning. Treatment options that achieve critical endpoints such as clinical remission and endoscopic response can make a difference in managing the challenging symptoms of this condition and health-related outcomes related to quality of life," said Jean-Frédéric Colombel, M.D., professor of medicine and director of Inflammatory Bowel Disease Center, Icahn School of Medicine, Mount Sinai and study investigator. "Upadacitinib could be a promising treatment option for patients who live with uncontrolled moderate to severe Crohn's disease. I look forward to the European Commission's final decision."
RINVOQ is approved in the EU for the treatment of adults with radiographic axial spondylarthritis, non-radiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, moderately to severely active ulcerative colitis and adults and adolescents with atopic dermatitis.
Use of upadacitinib in Crohn's disease is approved in Great Britain as of January 2023. Its safety and efficacy remain under evaluation in the European Union.
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain. It is a progressive disease, meaning it gets worse over time in a substantial proportion of patients or may develop complications that require urgent medical care, including surgery. Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically, but also emotionally and economically.
Read also: AbbVie raises sales outlook of Skyrizi, Rinvoq to USD 17.5 billion in 2025
2 years 5 months ago
News,Industry,Pharma News,Latest Industry News
Health & Wellness | Toronto Caribbean Newspaper
The History of vegan activist; the veganism movement started a long time ago
BY RACHEL MARY RILEY Have you ever heard the term that history truly repeats itself? The veganism movement started a long time ago. There are many perspectives on being a vegan, either way there are its benefits and cons. Some activists back in the day had a revelation about vegan life. I have a few […]
The post The History of vegan activist; the veganism movement started a long time ago first appeared on Toronto Caribbean Newspaper.
2 years 5 months ago
Fitness, #LatestPost
HIV Vaccine Candidate Stops Virus As it Enters Body
Researchers at the Texas Biomedical Research Institute are developing a vaccine candidate against HIV. The vaccine is intended to block HIV entry into the body and is administered to the mucosal lining of the rectum and vagina to achieve this. The formulation then stimulates antibodies against HIV in precisely the areas where the virus first enters the body’s cells. Cleverly, the researchers designed the vaccine to target the basal cells of the epithelium, which then give rise to a constant supply of epithelial cells to replace cells that are routinely sloughed off. This may lead to long-term protection against HIV with this vaccine. In tests with primates, the vaccine has shown significant efficacy in reducing viral transmission, and when vaccinated animals did become infected, they were able to control the infection much better and showed no disease symptoms.
HIV has evaded our best attempts to create an effective vaccine for decades. Although anti-retroviral therapy can allow people with HIV infection to live normal lives and avoid progression to AIDS, it still requires that someone takes these treatments for the rest of their lives. Moreover, these treatments may not be widely available for everyone, and lack of access can be an issue in low-resource areas. A vaccine that prevents people from getting infected with HIV in the first place, and allows them to control the infection if it does occur, would be very useful.
Part of the issue is that HIV spreads through the body relatively quickly. In response, these researchers had the idea of developing a vaccine that acts specifically on the areas of the body where the virus typically enters – the mucosal lining of the vagina or rectum. The concept is to give the virus a hard time before it even gets a chance to get a foothold in the body. “I had this idea as a postdoc,” said Marie-Claire Gauduin, a researcher involved in the study. “I thought it had to be naïve because nobody was talking about it. It was so obvious and simple to me; I thought someone would have already done it.”
The vaccine is a live attenuated vaccine, meaning that the viral particles within contain the full genetic code, albeit with some alterations to prevent the virus from replicating. The researchers describe the resulting particles as “single-cycle” vaccine virus. These modified viral particles can enter cells in the mucosa, but cannot proliferate and leave the cells again. The immune system can recognize that these cells are ‘infected’ and so generates antibodies against the virus, which will give any real virus attempting to enter the mucosa a hard time.
Cleverly, the vaccine targets cells in the mucosa that give rise to new cells, helping to keep the vaccine effective for as long as possible. “The idea is that as long as the vaccine is in the mother cells, it will be passed on and be present in all new epithelial cells in these regions,” said Gauduin. “I did not think it would work so well, but it did!”
In tests in non-human primates, the vaccine candidate helped animals to avoid infection in the first place, and once infected they showed a better ability to control the virus and showed no disease symptoms. It’s too early to know if the vaccine will work in humans, but the researchers have recently received some funding to develop it further.
2 years 5 months ago
Medicine, Public Health, aids, hiv, txbiomed
Why even low LDL cholesterol levels can pose a risk to your heart: New study sheds light - The Indian Express
- Why even low LDL cholesterol levels can pose a risk to your heart: New study sheds light The Indian Express
- Statins, Thiazides can increase blood sugar,risk of diabetes mycouriertribune.com
- View Full Coverage on Google News
2 years 5 months ago
Health Archives - Barbados Today
Vaccination schedule for February 27 to March 3, 2023
The Sinopharm and Johnson & Johnson COVID-19 vaccines will be available at the island’s polyclinics from Monday, February 27, to Friday, March 3, at the times listed below.
The Sinopharm and Johnson & Johnson COVID-19 vaccines will be available at the island’s polyclinics from Monday, February 27, to Friday, March 3, at the times listed below.
Monday, February 27
- Branford Taitt Polyclinic, Black Rock, St. Michael – 9:30 a.m. to 3:00 p.m.
- Eunice Gibson Polyclinic, Warrens, St. Michael – 1:30 p.m. to 3:30 p.m.
- Frederick “Freddie” Miller Polyclinic, The Glebe, St. George – 1:30 p.m. to 3:30 p.m.
Tuesday, February 28
- Branford Taitt Polyclinic, Black Rock, St. Michael – 9:30 a.m. to 3:00 p.m.
- Frederick “Freddie” Miller Polyclinic, The Glebe, St. George – 1:30 p.m. to 3:30 p.m.
- Eunice Gibson Polyclinic, Warrens, St. Michael – 1:30 p.m. to 3:30 p.m.
- Randal Phillips Polyclinic, Oistins, Christ Church – 2:00 p.m. to 4:00 p.m.
Wednesday, March 1
- Branford Taitt Polyclinic, Black Rock, St. Michael – 9:30 a.m. to 3:00 p.m.
- Maurice Byer Polyclinic, Station Hill, St. Peter – 10:00 a.m. to 2:00 p.m.
- Winston Scott Polyclinic, Jemmotts Lane, St. Michael – 1:00 p.m. to 3:00 p.m.
- St. Philip Polyclinic, Six Roads, St. Philip – 1:00 p.m. to 3:00 p.m.
- Edgar Cochrane Polyclinic, Wildey, St. Michael – 1:00 p.m. to 3:30 p.m.
- Eunice Gibson Polyclinic, Warrens, St. Michael – 1:30 p.m. to 3:30 p.m.
- Frederick “Freddie” Miller Polyclinic, The Glebe, St. George – 1:30 p.m. to 3:30 p.m.
Thursday, March 2
- Branford Taitt Polyclinic, Black Rock, St. Michael – 9:30 a.m. to 3:00 p.m.
- Frederick “Freddie” Miller Polyclinic, The Glebe, St. George – 1:30 p.m. to 3:30 p.m.
- Randal Phillips Polyclinic, Oistins, Christ Church – 2:00 p.m. to 4:00 p.m.
Friday, March 3
- David Thompson Health and Social Services Complex, Glebe Land, St. John – 9:00 a.m. to 3:00 p.m.
- Branford Taitt Polyclinic, Black Rock, St. Michael – 9:30 a.m. to 3:00 p.m.
- Frederick “Freddie” Miller Polyclinic, The Glebe, St. George – 1:30 p.m. to 3:30 p.m.
The AstraZeneca, adult Pfizer vaccine, and the paediatric Pfizer vaccine for children ages five to eleven, are currently not available.
Persons who wish to receive their first dose of any available vaccine are advised to walk with their identification card. Those eligible for second doses should also travel with their blue vaccination card.
At present, the choice for boosters is either Johnson & Johnson or Sinopharm. Persons receiving boosters may present either their blue vaccination card or vaccination certificate and valid photo identification. Those who were fully vaccinated overseas must also provide their vaccination cards and valid photo identification (passport or identification card). (MR/BGIS)
The post Vaccination schedule for February 27 to March 3, 2023 appeared first on Barbados Today.
2 years 5 months ago
A Slider, COVID-19, Health, Health Care, Local News
New guidance: Use drugs, surgery early for obesity in kids
WALTHAM, Massachusetts (AP) – Children struggling with obesity should be evaluated and treated early and aggressively, with medications for kids as young as 12 and surgery for those as young as 13 who qualify, according to new guidelines released by the American Academy of Paediatrics (AAP) last month.
A study published in the New England Journal of Medicine in December 2022, found that Wegovy helped teens reduce their body mass index by about 16 per cent on average, better than the results in adults.
The long-standing practice of "watchful waiting", or delaying treatment to see whether children and teens outgrow or overcome obesity on their own only worsens the problem that affects more than 14.4 million young people in the US. Left untreated, obesity can lead to lifelong health problems, including high blood pressure, diabetes and depression.
"Waiting doesn't work," said Dr Ihuoma Eneli, co-author of the first guidance on childhood obesity in 15 years from the AAP.
"What we see is a continuation of weight gain and the likelihood that they'll have [obesity] in adulthood."
For the first time, the group's guidance sets ages at which kids and teens should be offered medical treatments such as drugs and surgery — in addition to intensive diet, exercise and other behaviour and lifestyle interventions, said Eneli, director of the Centre for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio.
In general, doctors should offer adolescents 12 and older who have obesity access to appropriate drugs and teens 13 and older with severe obesity referrals for weight-loss surgery, though situations may vary.
The guidelines aim to reset the inaccurate view of obesity as "a personal problem, maybe a failure of the person's diligence", said Dr Sandra Hassink, medical director for the AAP Institute for Healthy Childhood Weight, and a co-author of the guidelines.
"This is not different than you have asthma and now we have an inhaler for you," Hassink said.
Young people who have a body mass index that meets or exceeds the 95th percentile for kids of the same age and gender are considered obese. Kids who reach or exceed that level by 120 per cent are considered to have severe obesity. BMI is a measure of body size based on a calculation of height and weight.
Obesity affects nearly 20 per cent of kids and teens in the US and about 42 per cent of adults, according to the Centres for Disease Control and Prevention (CDC).
The group's guidance takes into consideration that obesity is a biological problem and that the condition is a complex, chronic disease, said Aaron Kelly, co-director of the Centre for Paediatric Obesity Medicine at the University of Minnesota.
"Obesity is not a lifestyle problem. It is not a lifestyle disease," he said. "It predominately emerges from biological factors."
The guidelines come as new drug treatments for obesity in kids have emerged, including approval late last month of Wegovy, a weekly injection, for use in children ages 12 and older. Different doses of the drug, called semaglutide, are also used under different names to treat diabetes. A recent study published in the New England Journal of Medicine found that Wegovy, made by Novo Nordisk, helped teens reduce their BMI by about 16 per cent on average, better than the results in adults.
Within days of the December 23 authorisation, paediatrician Dr Claudia Fox had prescribed the drug for one of her patients, a 12-year-old girl.
"What it offers patients is the possibility of even having an almost normal body mass index," said Fox, also a weight management specialist at the University of Minnesota. "It's like a whole different level of improvement."
The drug affects how the pathways between the brain and the gut regulate energy, said Dr Justin Ryder, an obesity researcher at Lurie Children's Hospital in Chicago.
"It works on how your brain and stomach communicate with one another and helps you feel more full than you would be," he said.
Still, specific doses of semaglutide and other anti-obesity drugs have been hard to get because of recent shortages caused by manufacturing problems and high demand, spurred in part by celebrities on TikTok and other social media platforms boasting about enhanced weight loss.
In addition, many insurers won't pay for the medication, which costs about $1,300 a month. "I sent the prescription yesterday," Fox said.
"I'm not holding my breath that insurance will cover it."
One expert in paediatric obesity cautioned that while kids with obesity must be treated early and intensively, he worries that some doctors may turn too quickly to drugs or surgery.
"It's not that I'm against the medications," said Dr Robert Lustig, a long-time specialist in paediatric endocrinology at the University of California, San Francisco.
"I'm against the willy-nilly use of those medications without addressing the cause of the problem."
Lustig said children must be evaluated individually to understand all of the factors that contribute to obesity. He has long blamed too much sugar for the rise in obesity. He urges a sharp focus on diet, particularly ultra processed foods that are high in sugar and low in fibre.
Dr Stephanie Byrne, a paediatrician at Cedars Sinai Medical Centre in Los Angeles, said she'd like more research about the drug's efficacy in a more diverse group of children and about potential long-term effects before she begins prescribing it regularly.
"I would want to see it be used on a little more consistent basis," she said.
"And I would have to have that patient come in pretty frequently to be monitored."
At the same time, she welcomed the group's new emphasis on prompt, intensive treatment for obesity in kids.
"I definitely think this is a realisation that diet and exercise is not going to do it for a number of teens who are struggling with this — maybe the majority," she said.
2 years 5 months ago
A woman dies every two minutes due to pregnancy or childbirth, says UN agencies
GENEVA/NEW YORK/WASHINGTON (WHO) — Every two minutes, a woman dies during pregnancy or childbirth, according to the latest estimates released in a report by United Nations (UN) agencies today.
This report, 'Trends in maternal mortality', reveals alarming setbacks for women's health over recent years, as maternal deaths either increased or stagnated in nearly all regions of the world.
"While pregnancy should be a time of immense hope and a positive experience for all women, it is tragically still a shockingly dangerous experience for millions around the world who lack access to high quality, respectful health care," said Dr Tedros Adhanom Ghebreyesus, director general of the World Health Organization (WHO).
"These new statistics reveal the urgent need to ensure every woman and girl has access to critical health services before, during and after childbirth, and that they can fully exercise their reproductive rights."
The report, which tracks maternal deaths nationally, regionally and globally from 2000 to 2020, shows there were an estimated 287 000 maternal deaths worldwide in 2020. This marks only a slight decrease from 309 000 in 2016 when the UN Sustainable Development Goals (SDGs) came into effect. While the report presents some significant progress in reducing maternal deaths between 2000 and 2015, gains largely stalled, or in some cases even reversed, after this point.
In two of the eight UN regions — Europe and Northern America, and Latin America and the Caribbean — the maternal mortality rate increased from 2016 to 2020 by 17 per cent and 15 per cent, respectively. Elsewhere, the rate stagnated. The report notes, however, that progress is possible. For example, two regions — Australia and New Zealand, and Central and Southern Asia — experienced significant declines (by 35 per cent and 16 per cent respectively) in their maternal mortality rates during the same period, as did 31 countries across the world.
"For millions of families, the miracle of childbirth is marred by the tragedy of maternal deaths," said UNICEF Executive Director Catherine Russell.
"No mother should have to fear for her life while bringing a baby into the world, especially when the knowledge and tools to treat common complications exist. Equity in health care gives every mother, no matter who they are or where they are, a fair chance at a safe delivery and a healthy future with their family."
In total numbers, maternal deaths continue to be largely concentrated in the poorest parts of the world and in countries affected by conflict. In 2020, about 70 per cent of all maternal deaths were in sub-Saharan Africa. In nine countries facing severe humanitarian crises, maternal mortality rates were more than double the world average (551 maternal deaths per 100 000 live births, compared to 223 globally).
"This report provides yet another stark reminder of the urgent need to double down on our commitment to women and adolescent health," said Juan Pablo Uribe, global director for health, nutrition and population at the World Bank, and director of the Global Financing Facility.
"With immediate action, more investments in primary health care and stronger, more resilient health systems, we can save lives, improve health and well-being, and advance the rights of and opportunities for women and adolescents."
Severe bleeding, high blood pressure, pregnancy-related infections, complications from unsafe abortion, and underlying conditions that can be aggravated by pregnancy (such as HIV/AIDS and malaria) are the leading causes of maternal deaths. These are all largely preventable and treatable with access to high-quality and respectful health care.
Community-centred primary health care can meet the needs of women, children and adolescents and enable equitable access to critical services such as assisted births and pre- and postnatal care, childhood vaccinations, nutrition and family planning. However, underfunding of primary health-care systems, a lack of trained health-care workers, and weak supply chains for medical products are threatening progress.
Roughly a third of women do not have even four of a recommended eight antenatal checks or receive essential postnatal care, while some 270 million women lack access to modern family planning methods. Exercising control over their reproductive health — particularly decisions about if and when to have children — is critical to ensure that women can plan and space childbearing and protect their health. Inequities related to income, education, race or ethnicity further increase risks for marginalised pregnant women, who have the least access to essential maternity care but are most likely to experience underlying health problems in pregnancy.
"It is unacceptable that so many women continue to die needlessly in pregnancy and childbirth. Over 280,000 fatalities in a single year is unconscionable," said UNFPA Executive Director Dr Natalia Kanem.
"We can and must do better by urgently investing in family planning and filling the global shortage of 900,000 midwives so that every woman can get the lifesaving care she needs. We have the tools, knowledge and resources to end preventable maternal deaths; what we need now is the political will."
The COVID-19 pandemic may have further held back progress on maternal health. Noting the current data series ends in 2020, more data will be needed to show the true impacts of the pandemic on maternal deaths. However, COVID-19 infections can increase risks during pregnancy, so countries should take action to ensure pregnant women and those planning pregnancies have access to COVID-19 vaccines and effective antenatal care.
"Reducing maternal mortality remains one of the most pressing global health challenges," said John Wilmoth, director of the population division of the Department of Economic and Social Affairs.
"Ending preventable maternal deaths and providing universal access to quality maternal health care require sustained national and international efforts and unwavering commitments, particularly for the most vulnerable populations. It is our collective responsibility to ensure that every mother, everywhere, survives childbirth, so that she and her children can thrive."
The report reveals that the world must significantly accelerate progress to meet global targets for reducing maternal deaths, or else risk the lives of over 1 million more women by 2030.
2 years 5 months ago
Zero Discrimination Day
SOCIO-CULTURAL and religious norms and archaic policies and laws that criminalise and don't protect the rights of vulnerable populations contribute significantly to the HIV epidemic in the Caribbean. These societal barriers are fault lines which allow inequalities to widen and fester as a canker.
The Caribbean is the second highest region globally, outside sub–Saharan Africa, where HIV is prevalent. A little under half of people in the region do not show acceptable attitudes to people living with HIV. This is happening within the context of significant progress the region is making in reducing new HIV infections by 28 per cent between 2010 and 2021. AIDS-related deaths reduced by over half in the same period.
Can you imagine how this region would have performed without an environment with punitive laws, stigma and discrimination and gender-based violence?
It is important to identify and address the inequalities that exist in the region by promoting inclusion and respect for diversity. Building a just society involves understanding socio-cultural and gender norms and how they are changing and shaping how we interact to advance our civic, political, and economic rights. These norms, policies and practices affect how people access the services they need to safeguard their health, livelihood, and well-being and, importantly, enjoy their rights.
The Caribbean region cannot end the AIDS epidemic as a public health threat by 2030 without dealing with these societal barriers preventing the region from fulfilling the promise made by its leaders in the 2021 Political Declaration. This is how we build equal and just societies.
The focus of this year's Zero Discrimination Day, which is observed annually on March 1, is on decriminalization and how it saves the lives of vulnerable and marginalized populations and people living with HIV (PLHIV).
The Joint United Nations Programme on HIV/AIDS (UNAIDS) believes criminal laws targeting key populations and people living with HIV violate their human rights, make them vulnerable, increase their risk to HIV transmission and exacerbate the stigma people face. This put people in danger by creating barriers to the support and services they need to protect their health. These are the key elements of structural inequalities which are unfortunately driving the HIV epidemic globally and therefore preventing people from realising improvement in their health and well-being. The Caribbean is no exception. However, political leaders in the region can lead and show the world how being inclusive is a strength and not a weakness or threat to building an equal and just society committed to ending AIDS as a public health threat.
UNAIDS data show that 134 countries, including six in the Caribbean, still explicitly criminalise or otherwise prosecute HIV exposure, non-disclosure, or transmission. Twenty countries criminalise and/or prosecute transgender persons. Data show as well that 153 countries, including 14 countries from the Caribbean, criminalise at least one aspect of sex work and 67 countries, including eight in the region, that criminalise consensual same-sex sexual activity. Furthermore, 48 countries, including five countries in the Caribbean, still place restrictions on entry into their territory for people living with HIV while 53 countries report that they require mandatory HIV testing, for example, for marriage certificates or for performing certain professions. Finally, 106 countries require parental consent for adolescents to access HIV testing. All Caribbean countries apart from Guyana require parental consent for HIV testing. These legal and policy barriers are making it difficult for the world to close the chapter on the AIDS epidemic.
World leaders made a promise to address these difficult issues by agreeing for the first time to achieving the "10-10-10 targets". They made a commitment that by 2025 less than 10 per cent of countries would have punitive legal and policy environments that affect the HIV response; less than 10 per cent of countries reporting stigma and discrimination against key populations and persons living with HIV and finally less than 10 per cent of countries report gender-based violence against women and girls.
As we celebrate Zero Discrimination Day under the theme 'Save lives: Decriminalise', we are reminded of these commitments. Punitive and discriminatory laws across the region are harmful, they help to strip people living with HIV and key populations of their rights and are inimical to accelerating the end of AIDS as a public health threat in the region. UNAIDS therefore calls on all Caribbean governments to recommit to the principles of rights and take steps to fulfil their obligations to protect and promote human rights for all.
The Caribbean region can end the AIDS epidemic by improving the human rights environment through legal and policy reforms to respect, protect and fulfil the rights of vulnerable key populations and persons living with HIV to enhance access to critical health services they need. This is the pathway to building an equal and just society and to leave no one behind.
Dr Richard Amenyah is medical doctor and public health specialist from Ghana. He is the UNAIDS Multi-Country Director for the Caribbean. Send feedback to jamaica@unaids.org or follow him on Twitter @RichardAmenyah and @UNAIDSCaribbean.
2 years 5 months ago
VIDEO: ‘Fun and casual’ EnVision Summit empowers women in ophthalmology
In this Healio Video Perspective from the EnVision Summit, Judy E. Kim, MD, provides an overview of why ophthalmologists should attend the meeting in Puerto Rico.“It is a meeting for women ...
to support and empower early- and mid-career women in ophthalmology, fellows and residents, for them to come and present, gain podium opportunities, and interact with industry sponsors and each other,” she said. “It is a wonderful way to support and advance women in ophthalmology.”
2 years 5 months ago
Government affirms hospitals are in operation
Santo Domingo, DR.
The National Health Service (SNS) clarified yesterday that the Padre Billini Teaching Hospital, handed over in the middle of last year by President Luis Abinader, is functioning at full capacity, with its areas and services available to citizens who come to the health center in search of health care.
Santo Domingo, DR.
The National Health Service (SNS) clarified yesterday that the Padre Billini Teaching Hospital, handed over in the middle of last year by President Luis Abinader, is functioning at full capacity, with its areas and services available to citizens who come to the health center in search of health care.
As announced in a press release last week, the Intensive Care Unit, Operating Theatres, and Admission areas, which completed 100 percent of the iconic hospital’s services, were enabled the previous week.
It is recalled that the modern dental area of Padre Billini was put into service in January. It has two dental units, two periapical X-rays, a sterilizer, and a panoramic X-ray.
The portfolio of services of the health center, available to the public, includes Emergency, Outpatient, Laboratory, Imaging, Haemodialysis Unit, Blood Bank, Pharmacy, Tuberculosis Unit, Nutrition, Pathology, Endoscopy, High-Cost Programme (Rheumatology and Haematology) and Liver Programme. From its inauguration in August 2022 to January 2023, the Padre Billini Hospital has offered 101,174 services, such as emergencies, imaging, and laboratories.
Villa Hermosa
The SNS reported that the Villa Hermosa Hospital in La Romana has the necessary staff and equipment to offer services.
As announced during the inauguration, work is based on a schedule for opening services that begins on 13 March with outpatient consultations (six clinics), laboratory, imaging (ultrasound and X-rays), and dentistry.
On 3 April, the emergency room will come into service; on 17 April, the in-patient ward and the intensive care unit, while on 1 May, the operating theatres will be ready for use, leaving the commissioning process at 100%, just two months after its handover.
During the handover, which took place on the 24th of this month, the SNS announced that the health center has now entered the qualification stage by the Ministry of Public Hea. In this protocol phase, each process is supervised to qualify it and affiliate it to the various Health Risk Administrators (ARS) and thus guarantee the hospital’s and its structure’s sustainability.
The SNS is working on training staff in the proper handling of the advanced equipment available at the facility, and this induction began once the equipment was installed.
The National Health Service reported that as soon as other health centers intervened under the Ministry of Housing and Building (MIVED) management delivered, the commissioning process will begin, which is continuously published during inaugurations.
2 years 5 months ago
Health, Local
Why it's important to recognize your risk for heart disease - KSL.com
- Why it's important to recognize your risk for heart disease KSL.com
- Expert gives 7 lifestyle strategies to prevent heart diseases INQUIRER.net
- Why is heart care important | Health Jamaica Gleaner
- View Full Coverage on Google News
2 years 5 months ago
Could a urine test detect pancreatic and prostate cancer? Study shows 99% success rate
A simple urine test could detect pancreatic and prostate cancer with up to a 99% rate of accuracy, says a team of researchers from the Surface & Nano Materials Division of the Korea Institute of Materials Science.
A simple urine test could detect pancreatic and prostate cancer with up to a 99% rate of accuracy, says a team of researchers from the Surface & Nano Materials Division of the Korea Institute of Materials Science.
Dr. Ho Sang Jung, lead author of the study, said cancer urine contains cancer metabolites and is different from normal urine.
The study, recently published in the journal Biosensors and Bioelectronics, aimed to determine whether urine tests could detect those cancer metabolites, which are released by cancer cells to promote tumor growth.
NORTH CAROLINA MAN DEVELOPED 'UNCONTROLLABLE' IRISH ACCENT DURING PROSTATE CANCER TREATMENT
After the urine sample was placed on a test strip, the researchers used a special type of light scattering technique that generated a "fingerprint spectrum of chemicals," which detected the cancer metabolites.
Dr. Jung said the tests can detect cancer at various stages.
"The purpose of developing this kind of technology is to screen the cancer patient before they go to the hospital," he told Fox News Digital in an email.
"We are not sure that the test strip can differentiate cancer at very early stages, but at least it can suggest the possibility of cancer status — so the patient may then go to the hospital for a precise medical checkup."
PANCREATIC CANCER RATES ARE RISING FASTER AMONG WOMEN THAN MEN: NEW STUDY
Dr. James Anaissie, a urologist with Memorial Hermann in Houston, Texas, who was not involved in the study, is optimistic about the future of this technology — but he’s not jumping completely on board just yet.
"If the test is as reliable as they say it is, it may have an important role in screening, as the current PSA [prostate-specific antigen] blood test we use is notoriously unreliable," he told Fox News Digital in an email.
"There is a big need for something like this."
Also, from a clinical perspective, urine testing is much easier than blood testing, the doctor said.
However, Anaissie remains a bit skeptical.
"Although they report excellent sensitivity and specificity for prostate cancer, the data to support this is only available upon request of the research team, and they have almost no tables demonstrating these findings, which I would consider standard for studies of this nature," he said.
BREAST CANCER AND MAMMOGRAMS: EVERYTHING YOU NEED TO KNOW ABOUT THE DISEASE, SCREENING AND MORE
"For example, were the patients diagnosed with prostate cancer in severe stages, where it’s obvious they have prostate cancer even without any urine tests?" said Dr. Anaissie.
"Was it just as accurate for low-grade and high-grade cancers? Whenever I hear about exciting new technology, I’m always receptive, but with a raised eyebrow."
Urine screenings can be used by anyone, said Dr. Jung. The end goal is for this type of technology to be available for at-home testing.
He foresees several possible practical uses, including screening for cancer before going to the hospital, monitoring for cancer recurrence after treatment, or supplementary testing in addition to blood work.
The study authors recognize some limitations of the research.
"It was hard to get enough urine samples from cancer patients," said Dr. Jung.
His team used 100 samples in the study and is continuously collecting more from hospitals throughout Korea.
Also, because this is a new technology, it still has not been approved by the Ministry of Food and Drug Safety in Korea for commercial use.
Anaissie also points out that more studies are needed to see if the test works when there is a urinary tract infection or blood in the urine, which is not uncommon in patients with prostate cancer.
TOXIC CHEMICAL POISONING: HAVE YOU BEEN AFFECTED? HOW TO KNOW
"Technology like this takes a long time to go from the lab’s proof of concept to everyday use, and a lot of people are going to try to pick it apart to make sure it’s safe and reliable," Anaissie said.
"The last thing you want is a screening test that ends up having a lot of false negatives. If it can survive the scrutiny, then it has the potential to revolutionize prostate cancer screening."
The researchers’ ultimate goal is for the urine screenings to extend eventually to other types of cancers, such as lung cancer and colorectal cancer.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
"We are currently developing a system that can classify four cancer types — pancreatic cancer, prostate cancer, lung cancer and colorectal cancer — simultaneously," Jung told Fox News Digital.
He expects the follow-up study to be published sometime this year.
Pancreatic cancer makes up around 3% of cancer diagnoses in the U.S. and 7% of deaths, per the American Cancer Society (ACS).
Men are slightly more susceptible than women.
Prostate cancer is the most common type of cancer among American men, with about one in 41 dying of the disease (via the ACS).
2 years 5 months ago
Health, medical-research, Cancer, pancreatic-cancer, prostate-cancer, lifestyle
PAHO/WHO | Pan American Health Organization
Onchocerciasis or "river blindness" - a disease that affects the poorest in rural areas
Onchocerciasis or "river blindness" - a disease that affects the poorest in rural areas
Cristina Mitchell
24 Feb 2023
Onchocerciasis or "river blindness" - a disease that affects the poorest in rural areas
Cristina Mitchell
24 Feb 2023
2 years 5 months ago
Cancer patients have difficulty accessing treatment
Preventive education, early detection, access to treatment, coverage of health services, and promoting active participation of patients in decision-making, are the main challenges facing the Dominican Republic in the fight against cancer.
In recent years there has been an improvement in the application of diagnostic techniques and the use of precision medicine to enhace the efficiency of treatments and patient care and the best strategy in the fight against cancer is multi-disciplinary management: prevention controls, early detection, and equal access.
The topic was exposed by patients and oncology specialists during the discussion “Comprehensive Vision and Cancer Challenges in the Dominican Republic”, held at the Santo Domingo Technological Institute (INTEC). The president of Fundación Un Amigo Como Tú, Juan Manuel Pérez, shared his experience as a survivor of non-Hodgkin Lymphoma. He said that these limitations are compounded by the emotional impact of receiving the diagnosis and the lack of information about the causes of the disease.
He added that cancer patients face late diagnoses and insufficient coverage for drugs and services. In turn, Dr. Mariel Pacheco del Castillo, pathologist and master’s degree in Molecular Oncology, said that today the objective of cancer treatment must be to restore a state of complete physical, mental, and social well-being in patients and not only eradicate the tumor burden.
2 years 5 months ago
Health, Local
Montana Seeks to Insulate Nursing Homes From Future Financial Crises
Wes Thompson, administrator of Valley View Home in the northeastern Montana town of Glasgow, believes the only reasons his skilled nursing facility has avoided the fate of the 11 nursing homes that closed in the state last year are local tax levies and luck.
Valley County, with a population of just over 7,500, passed levies to support the nursing home amounting to an estimated $300,000 a year for three years, starting this year. And when the Hi-Line Retirement Center in neighboring Phillips County shut down last year as the covid-19 pandemic brought more stressors to the nursing home industry, Valley View Home took in some of its patients.
Thompson said he foresees more nursing home closures on the horizon as their financial struggles continue. But lawmakers are trying to reduce that risk through measures that would raise and set standards for the Medicaid reimbursement rates that nursing homes depend on for their operations.
A study commissioned by the last legislative session found that Medicaid providers in Montana were being reimbursed at rates much lower than the cost of care. In his two-year state budget proposal before lawmakers, Republican Gov. Greg Gianforte has proposed increases to the provider rates that fall short of the study’s recommendations.
Legislators drafting the state health department budget included rates higher than the governor’s proposal, but still not enough for nursing homes to cover the cost of providing care. Those rates are subject to change as the state budget bill goes through the months-long legislative process, though majority-Republican lawmakers so far have rejected Democratic lawmakers’ attempts for full funding.
In a separate effort to address the long-term care industry’s long-term viability, a bipartisan bill going through Montana’s legislature, Senate Bill 296, aims to revise how nursing homes and assisted living facilities are funded. The bill would direct health officials to consider inflation, cost-of-living adjustments, and the actual costs of services in setting Medicaid reimbursement rates.
SB 296, which received an initial hearing on Feb. 17, has generated conflicting opinions from experts in the long-term care field on whether it does enough to avoid nursing home closures.
Republican Sen. Becky Beard, the bill’s sponsor, said that although the bill comes too late for the nursing homes that have already closed, she sees it as shining a light on a problem that’s not going away.
“We need to stop the attrition,” Beard said.
Sebastian Martinez Hickey, a research assistant at the Economic Policy Institute, a nonprofit think tank, said wages for nursing home employees had been extremely low even before the pandemic. He said the focus needs to be on raising Medicaid reimbursement rates beyond inflationary factors.
“Increasing Medicaid rates for inflation is going to have positive effects, but there’s no way that it’s going to compensate for what we’ve experienced in the last several years,” Martinez Hickey said.
Colorado, Illinois, Massachusetts, and North Carolina are among the states that have adopted laws or regulations to increase nursing home staff wages since the pandemic began. Michigan, North Carolina, and Ohio adopted increases or one-time bonuses.
In Maine, a 2020 study of long-term care workforce issues suggested that Medicaid rates should be high enough to support direct-care worker wages that amount to at least 125% of the minimum wage, which is $13.80 in that state. In combination with other goals outlined in the study, after a year there had been modest increases in residential care homes and beds, improved occupancy rates, and nods toward stabilization of the direct-care workforce.
Rose Hughes, executive director of the Montana Health Care Association, which lobbies on behalf of nursing homes and senior issues, said many of the problems plaguing senior care come down to reimbursement rates. There’s not enough money to hire staff, and, if there were, wages would still be too low to attract staff in a competitive marketplace, Hughes said.
“It’s trying to deal with systemic problems that exist in the system so that longer term the reimbursement system can be more stable,” Hughes said.
The governor’s office said Gianforte has been clear that Montana needs to raise its provider rates. For senior and long-term care, Gianforte’s proposed state budget would raise provider rates to 88% of the benchmark recommended by the state-commissioned study. Gianforte’s budget proposal is a starting point for lawmakers, and legislative budget writers have penciled in funding at about 90% of the benchmark rate.
“The governor continues to work with legislators and welcomes their input on his historic provider rate investment,” Gianforte spokesperson Kaitlin Price said.
Democratic Rep. Mary Caferro is sponsoring a bill to fully fund the Medicaid provider rates in accordance with the study.
“What we really, really need is our bill to pass so that it brings providers current with ongoing funding for predictability and stability so they can do the good work of caring for people,” Caferro said at a Feb. 21 press briefing.
But Thompson said that even the reimbursement rate recommended by the study — $279 per patient, per day, compared with the current $208 rate — isn’t high enough to cover Valley View Home’s expenses. He said he’s going to have to have a “heart to heart” with the facility’s board to see what can be done to keep it open if the local tax levies in combination with the new rate aren’t enough to cover the cost of operations.
David Trost, CEO of St. John’s United, an assisted-living facility for seniors in Billings, said the current reimbursement rate is so low that St. John’s uses savings, grants, fundraising revenue, and other investments to make up the difference. He said that while SB 296 looks at factors to cover operating costs, it doesn’t account for other costs, such as repairs and renovations.
“In addition to paying for existing operating costs as desired by SB 296, we also need to look at funding of capital improvements through some loan mechanism to help nursing facilities make improvements to existing environments,” Trost said.
Another component of SB 296 seeks to boost assisted-living services by generating more federal funding.
Additional money could help reduce or eliminate the waiting list for assisted-living homes, which now stands at about 175 people, Hughes said. That waiting list not only signals that some seniors aren’t getting service, but it also results in more people being sent to nursing homes when they may not need that level of care.
SB 296 would also ensure that money appropriated to nursing homes can be used only for nursing homes, and not be available for other programs within the Department of Public Health and Human Services, like dentists, hospitals, or Medicaid expansion. According to Hughes, in 2021 the nursing home budget had a remainder of $29 million, which was transferred to different programs in the Senior and Long Term Care division.
If the funding safeguard in SB 296 had been in place at that time, Hughes said, there may have been more money to sustain the nursing homes that closed last year.
Keely Larson is the KHN fellow for the UM Legislative News Service, a partnership of the University of Montana School of Journalism, the Montana Newspaper Association, and Kaiser Health News. Larson is a graduate student in environmental and natural resources journalism at the University of Montana.
KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.
USE OUR CONTENT
This story can be republished for free (details).
2 years 5 months ago
Aging, Cost and Quality, Health Industry, Rural Health, States, Colorado, Illinois, Legislation, Maine, Massachusetts, Michigan, Montana, North Carolina, Nursing Homes, Ohio
NextGen COVID-19 Antibodies Destroy Spike Protein
Researchers at the Garvan Institute of Medical Research in Australia have developed a new generation of antibodies to treat COVID-19. So far, the antibodies have been shown to neutralize several of the viral variants behind COVID-19, and the researchers hope that they will form an effective treatment for at-risk patients. Previously developed antibody treatments for COVID-19 have been rendered largely useless as the virus has mutated. Such antibodies have focused on binding to the most obvious site on the viral spike protein, the ACE2 receptor binding site, but their efficacy in destroying the virus has waned with new viral variants. However, these new antibodies bind to a different site on the spike protein that is partially hidden, and appear to essentially rip the spike protein apart, prompting the researchers to surmise that the virus will find it hard to develop resistance.
SARS-CoV-2 continues to proliferate around the world. While vaccines have provided many of us with protection against severe disease, they do not offer the same level of protection for everyone. For instance, severely immunocompromised patients may not receive much benefit from current COVID-19 vaccines, and will likely require additional treatment if they contract the disease.
Developing new treatments for COVID-19 will greatly benefit such patients, but SARS-CoV-2 is a formidable adversary, with new variants popping up around the world. Unfortunately, previous iterations of antibody treatments for COVID-19 have been rendered largely ineffective by these mutations.
“Almost all commercially available antibodies for COVID-19 don’t work well anymore,” said Jake Henry, a researcher involved in the study. “Most are class 1 or 2, which refers to the fact that they bind to the most obvious spot on the spike protein – the ACE2 receptor binding site. They have downsides, including failure against new variants as they evolve. We’re delighted our research could lead to new antiviral therapy providing reliable ‘passive immunity’ to at-risk individuals.”
The new ‘class 6’ antibodies bind to a different part of the spike protein and can lead to its destruction. “This is a new mechanism of action we’re seeing with these class 6 antibodies,” said Daniel Christ, another researcher involved in the study. “Our hypothesis is that they’re so effective because the area we’re targeting is close to the center of the spike’s structure. When the antibody attaches there, it distorts the spike and rips it apart. It would be very difficult for the virus to adapt to that.”
Study in journal Nature Communications: Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients
2 years 5 months ago
Medicine, Public Health